Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 25, 2015 2:43 AM ET

Biotechnology

Company Overview of Lineagen, Inc.

Company Overview

Lineagen, Inc. provides genetic evaluation services in autism and developmental delay. The company focuses on genetic disorders, such as autism, multiple sclerosis, and chronic obstructive pulmonary disease. It provides FirstStep, which provides physicians with integrated genetic testing, counseling, and developmental screening services to aid in the clinical evaluation; and M-CHAT, an autism screening tool. The company also offers counseling services. It serves healthcare professionals, physicians, and individuals. The company was formerly known as GenData Research Corporation and changed its name in January 2005. Lineagen, Inc. was founded in 2002 and is based in Salt Lake City, Utah.

423 Wakara Way

Suite 200

Salt Lake City, UT 84108

United States

Founded in 2002

Phone:

801-931-6200

Fax:

801-931-6201

Key Executives for Lineagen, Inc.

Co-Founder, Chief Executive Officer, President and Director
Co-Founder and Senior Director of Product Management
Director of Finance
Chief Operating Officer
Chief Commercialization Officer
Age: 54
Compensation as of Fiscal Year 2014.

Lineagen, Inc. Key Developments

Lineagen, Inc. Announces Board Appointments

Lineagen, Inc. announced the closing of the second and final tranche of its $15.8 million Series C round of financing. David S. Kabakoff, Ph.D., partner of HeathQuest Capital, and David Fitzgerald of Petra Capital have joined the Lineagen Board of Directors in conjunction with the financing.

Lineagen, Inc. Announces Identification of 39 Genetic Variants as Novel Risk Factors for Developing Autism Spectrum Disorder

Lineagen, Inc. announced the publication of the first major study in autism spectrum disorder (ASD) to apply a unique research approach that identified 39 variants in 36 genes, which may confer a genetic risk of developing ASD. This approach -haplotype sharing in multi-generational families from the Utah Population Database (UPDB) -opens the door to more efficient elucidation of ASD gene risk variants and more powerful genetic diagnostic testing to assist in the clinical evaluation of individuals with ASD and related disorders of childhood development. Researchers affiliated with The Children's Hospital of Philadelphia (CHOP), the University of Utah (Utah), Golden Helix, Inc., and Lineagen participated in the study, which was designed to detect genetic variants that confer risk of developing ASD in large multi-generational families, and then testing those discoveries in a broader population of unrelated individuals with ASD. The results showed that 11 of the familial gene variants also confer a genetic risk of developing ASD in the general population. Importantly, three genetic variants discovered by Lineagen may be causal, as they were not detected in gene sequences from more than 10,000 individuals without a diagnosis of ASD. One of these variants was identified in the RAB11FIP5 gene that encodes a brain protein involved with synaptic glutamate receptor recycling, among other functions. Two separate variants were identified in the AKAP9 gene, a member of a larger gene family that independent studies have shown to be integral to many biological pathways implicated in the development of ASD. Results from Lineagen's study were published in the current issue of Molecular Autism.

Lineagen, Inc. Presents at 2014 Autism Investment Conference, Mar-04-2014 08:45 AM

Lineagen, Inc. Presents at 2014 Autism Investment Conference, Mar-04-2014 08:45 AM. Venue: Bently Reserve, 301 Battery St, San Francisco, CA 94111, United States. Speakers: Michael S. Paul, Co-Founder, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Flint Hills Scientific, LLC United States
Catalyst Biosciences, Inc. United States
Signal Pharmaceuticals, LLC United States
SureScreen Medical, Inc. United States
Sanford Applied Biosciences, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lineagen, Inc., please visit www.lineagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.